retatrutide phase 2 trial type 2 diabetes weight loss 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Lilly's triple agonist, retatrutide, successful

This position alone can reduce straining by up to 50% according to research published in the Journal of Clinical Gastroenterology

[2] [3] For many patients with established cardiovascular disease or high cardiovascular risk, SGLT2 inhibitors are preferred before GLP-1 receptor agonists where appropriate

Most do not find differences in sweet taste perception between individuals with and without obesity

In preclinical cellular models, the triple-receptor engagement profile of Retatrutide has been associated with modulation of AMP-activated protein kinase (AMPK) activity, alterations in fatty acid oxidation gene expression, and changes in hepatic glucose output markersthough the precise mechanistic contributions of each receptor axis remain an active area of investigation

..I wrote one-third of the LessWrong posts I've ever written in the last month [3]